Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel oral small molecule therapies targeting STAT3 (Signal Transducer and Activator of Transcription 3) to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a first-generation direct STAT3 inhibitor in Phase 1b/2 development for hepatocellular carcinoma (HCC), and TTI-109, a phosphate prodrug of TTI-101 in Phase 1 trial in healthy volunteers. The company has received FDA Orphan Drug Designation for TTI-101 in IPF and HCC, and Fast Track Designation for TTI-101 in HCC.
expected 2026-11-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001104659-26-037729 | EDGAR | 111K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002705 | EDGAR | 131K words |
| 2024-03-06 | 2023-12-31 | 0001558370-24-002609 | EDGAR | 100K words |
| 2023-03-06 | 2022-12-31 | 0001558370-23-002913 | EDGAR | 105K words |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002555 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001839 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001558370-20-001659 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007389 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001564590-18-005879 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001193125-17-077107 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001104659-26-096424 | EDGAR | 26K words |
| 2025-11-13 | 2025-09-30 | 0001104659-25-111289 | EDGAR | 80K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011562 | EDGAR | 79K words |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007575 | EDGAR | 79K words |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015713 | EDGAR | 73K words |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012231 | EDGAR | 70K words |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007964 | EDGAR | 34K words |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018837 | EDGAR | 46K words |
| 2023-08-07 | 2023-06-30 | 0001558370-23-013598 | EDGAR | 42K words |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009845 | EDGAR | 35K words |
| 2022-11-07 | 2022-09-30 | 0001558370-22-016625 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012626 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-14 | 0001104659-26-096417 | EDGAR | 2K words |
| 2026-07-30 | 0001104659-26-088461 | EDGAR | 11K words |
| 2026-07-17 | 0001104659-26-084627 | EDGAR | 1K words |
| 2026-03-31 | 0001104659-26-037724 | EDGAR | 3K words |
| 2026-03-06 | 0001104659-26-024676 | EDGAR | 1K words |
| 2026-01-16 | 0001104659-26-004273 | EDGAR | 5K words |
| 2025-12-18 | 0001104659-25-122615 | EDGAR | 2K words |
| 2025-11-19 | 0001104659-25-113901 | EDGAR | 4K words |
| 2025-11-13 | 0001104659-25-111310 | EDGAR | 3K words |
| 2025-10-14 | 0001104659-25-098908 | EDGAR | 1K words |
225 total filings indexed. 193 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001346830 |
| Ticker | TVRD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.tvarditherapeutics.com |
| Listed | 2025-04-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TVRD (~200 tokens, structured JSON with cryptographic provenance)